hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
24296Cm + 42He → 24598Cf + 10n Only about 5,000 atoms of californium were produced in this experiment. The odd-mass curium isotopes 243Cm, 245Cm, and 247Cm are all highly fissile and can release additional energy in a thermal spectrum nuclear reactor. All curium isotopes are fissionable in fast-neutron reactors. This is one of the motives for minor actinide separation and transmutation in the nuclear fuel cycle, helping to reduce the long-term radiotoxicity of used, or spent nuclear fuel.
=== Classifiers and statistical learning methods === The simplest AI applications can be divided into two types: classifiers (e.g., "if shiny then diamond"), on one hand, and controllers (e.g., "if diamond then pick up"), on the other hand. Classifiers are functions that use pattern matching to determine the closest match. They can be fine-tuned based on chosen examples using supervised learning. Each pattern (also called an "observation") is labeled with a certain predefined class. All the observations combined with their class labels are known as a data set. When a new observation is received, that observation is classified based on previous experience. There are many kinds of classifiers in use. The decision tree is the simplest and most widely used symbolic machine learning algorithm. K-nearest neighbour algorithm was the most widely used analogical AI until the mid-1990s, and Kernel methods such as the support vector machine (SVM) displaced k-nearest neighbour in the 1990s. The naive Bayes classifier is reportedly the "most widely used learner" at Google, due in part to its scalability. Neural networks are also used as classifiers.
== Sources == Cooper, Tom; Grandolini, Albert; Delalande, Arnaud (2015). Libyan Air Wars, Part 1: 1973-1985. Helion & Company Publishing. ISBN 978-1-909982-39-0. Cooper, Tom; Grandolini, Albert; Delalande, Arnaud (2016). Libyan Air Wars, Part 3: 1986-1989. Helion & Company Publishing. ISBN 978-1-910294-54-3. Cooper, Tom & Weinert, Peter (2010). African MiGs: Volume I: Angola to Ivory Coast. Harpia Publishing LLC. ISBN 978-0-9825539-5-4.
== Hydration states == Calcium sulfate occurs at three levels of hydration with different crystallographic structures: anhydrous, dihydrate, and hemihydrate. The anhydrous CaSO4 (anhydrite) crystallizes as an tightly-bound orthorhombic lattice with space group Pnma, in which each Ca2+ is 8-coordinated, or surrounded, by 8 oxygen atoms from tetrahedral SO2−4. It is similar in topology to zircon. The dihydrate CaSO4·2H2O (gypsum) forms a monoclinic crystal with space group C2/c. Its structure consists of alternating layers: one with Ca2+ coordinated with tetrahedral SO2−4 and another with interstitial water molecules. The hemihydrate CaSO4·1/2H2O (bassanite) is also known as plaster of Paris. Specific hemihydrates are sometimes distinguished between α-hemihydrate and β-hemihydrate.
Pauling had been practically apolitical until World War II. At the beginning of the Manhattan Project, Robert Oppenheimer invited him to be in charge of the Chemistry division of the project. He declined, not wanting to uproot his family.
Sources: en.wikipedia.org
Dunkin' Donuts LLC, doing business as Dunkin', is an American multinational fast food restaurant chain specializing in coffee and doughnuts. It was founded by Bill Rosenberg in Quincy, Massachusetts, in 1950. The chain was acquired by Baskin-Robbins' holding company Allied Lyons in 1990. Its acquisition of the Mister Donut chain and the conversion of that chain to Dunkin' Donuts facilitated the brand's growth in North America the same year. Dunkin' and Baskin-Robbins eventually became subsidiaries of Dunkin' Brands, headquartered in Canton, Massachusetts, in 2004. Dunkin' Brands was purchased by Inspire Brands on December 15, 2020. The chain began rebranding as a "beverage-led company", and was renamed Dunkin' in January 2019. While stores in the U.S. began using the new name, the company intends to roll out the rebranding to all of its international locations. With approximately 14,200 locations in 39 countries and $14.5 billion in system sales, Dunkin' is one of the largest coffee shop and doughnut shop chains in the world. In addition to several varieties of coffee and doughnuts, products sold include bagels, breakfast sandwiches, muffins, and doughnut holes branded as Munchkins.
Comintern (1919–1943), or Communist International, was an international communist organization based in the Kremlin that advocated world communism. The Comintern intended to 'struggle by all available means, including armed force, for the overthrow of the international bourgeoisie and the creation of an international Soviet republic as a transition stage to the complete abolition of the state'. It was abolished as a conciliatory measure toward Britain and the United States. Comecon, the Council for Mutual Economic Assistance (Russian: Совет Экономической Взаимопомощи, Sovet Ekonomicheskoy Vzaimopomoshchi, СЭВ, SEV) was an economic organization from 1949 to 1991 under Soviet control that comprised the countries of the Eastern Bloc along with several communist states elsewhere in the world. Moscow was concerned about the Marshall Plan, and Comecon was meant to prevent countries in the Soviets' sphere of influence from moving towards that of the Americans and Southeast Asia. Comecon was the Eastern Bloc's reply to the formation in Western Europe of the Organization for European Economic Co-Operation (OEEC), The Warsaw Pact was a collective defence alliance formed in 1955 among the USSR and its satellite states in Eastern Europe during the Cold War. The Warsaw Pact was the military complement to the Comecon, the regional economic organization for the socialist states of Central and Eastern Europe. The Warsaw Pact was created in reaction to the integration of West Germany into NATO.
Government Medical College, Patiala was proposed in October 1951 by the Patiala and East Punjab States Union government, under the First Five-Year Plan. The first batch was started on 29 September 1953. The classes initially started from the old building of the Rajindra Hospital, which later shifted to the Archives Department, about 2 kilometers from its current location. With the construction of the new Rajindra Hospital in 1953 the old hospital building was made available to house some of the offices of the PEPSU state. Currently the Archives Department is housed in the Rajindra Hospital, which was built in 1877 and opened in January 1883. The nearby Dufferin Hospital started construction in November 1888 and opened in October 1890. The Rajindra Hospital is named after Maharaja Sir Rajinder Singh and it receives a notable mention in 1908 by The Imperial Gazetteer of India as the Rajindra Hospital. The hospital was known as Rajindra Hospital in pre-independence era, was sometimes mentioned as Rajendra Hospital, and currently uses the name Rajindra Hospital. With its attached 1009-bed Rajindra Hospital + 121-bed TB hospital is one of the largest health institutions in the region. The attached central clinical laboratory with facilities for hematology, pathology, microbiology, biochemistry is known as Bhupindra Clinical Laboratory.
Sigma RBI produces specialized products for use in the field of cell signaling and neuroscience. Their offerings range from standard biochemical reagents to specialized research tools, including ligands for receptors and ion channels, enzyme inhibitors, phosphospecific antibodies, key signal transduction enzymes, and assay kits for cell signaling.
=== Mechanism of action === Phencyclidine is a noncompetitive NMDA receptor antagonist that blocks the activity of the NMDA receptor to cause anaesthesia and analgesia without causing cardiorespiratory depression. NMDA is an excitatory receptor in the brain, when activated normally the receptor acts as an ion channel and there is an influx of positive ions through the channel to cause nerve cell depolarisation. Phencyclidine inhibits the NMDA receptor by binding to the specific PCP binding site located within the ion channel. The PCP binding site is near the magnesium blocking site, which may explain the similar inhibitory effects. Binding at the PCP site is mediated by two non-covalent interactions within the receptor: hydrogen bonding and hydrophobic interaction. Binding is also controlled by the gating mechanism of the ion channel. Because the PCP site is located within the ion channel, a coagonist such as glycine must bind and open the channel for PCP to enter, bind to the PCP site, and block the channel.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.